Skip to main content

Alaunos Therapeutics, Inc.

TCRT
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001107421

No open-market purchases or sales by Alaunos Therapeutics, Inc. insiders were filed in the last 90 days; 29 institutions reported holding it in 13F filings for Q2 2026, worth $204.4K in total; no superinvestor holds it.

Q3 2024 vs. Q2 2024

How the institutions holding Alaunos Therapeutics, Inc. changed between Q2 2024 and Q3 2024.

All holders in Q3 2024All holders in Q2 2024

13F holders of TCRT: Q2 2024 compared with Q3 2024
MeasureQ2 2024Of which not filed for Q3 2024Q3 2024Change
Holders50129−20
SharesConverted for a 1-for-10 split241.0K22.2K192.1K−26.7K (−12.2%)
Value$1.69M$155.5K$622.8K−$912.6K (−59.4%)

1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.

New holders (4)

Institutions that held Alaunos Therapeutics, Inc. at the end of Q3 2024 but not at the end of Q2 2024.

Institutions new to TCRT in Q3 2024
InstitutionSharesValue% of portfolio
BlackRock, Inc.22,233$71.6K0.00%
Bokf, NA66$1810.00%
Harbour Investments, Inc.46$1480.00%
Chilton Capital Management LLC16$520.00%

Sold out (24)

Institutions that held Alaunos Therapeutics, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.

Not filed for Q3 2024 yet (1)

Institutions that held Alaunos Therapeutics, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding TCRT in Q2 2024 that haven't filed for Q3 2024
InstitutionShares, Q2 2024Value, Q2 2024
BlackRock Inc.222,440$155.5K